Carbon Monoxide

Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)

Also Known As:

Networked: 68732 relevant articles (2261 outcomes, 7816 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Choi, Augustine M K: 54 articles (01/2016 - 01/2002)
2.	Otterbein, Leo E: 51 articles (08/2015 - 04/2002)
3.	Kaprio, Jaakko: 42 articles (10/2015 - 03/2002)
4.	Drake, Robert E: 41 articles (01/2016 - 02/2002)
5.	Zhang, Wei: 41 articles (12/2015 - 01/2007)
6.	Li, Li: 41 articles (09/2015 - 01/2005)
7.	Lisanti, Michael P: 38 articles (10/2015 - 10/2008)
8.	Motterlini, Roberto: 38 articles (02/2014 - 02/2002)
9.	Wang, Wei: 37 articles (12/2015 - 12/2005)
10.	Ryter, Stefan W: 35 articles (01/2016 - 05/2002)

Related Diseases

1.	Infection 10/01/2015 - "The effect of HIV co-infection on HCV-related disease was clear with most studies indicating that HIV accelerates HCV progression and reduces the efficacy of the available anti-HCV therapies." 11/01/2010 - "To evaluate the impact of HIV co-infection with HCV or HBV on the efficacy of highly active anti-retroviral therapy (HARRT). " 06/01/2008 - "Although co-infection is the norm in most human and animal populations, clinicians currently have no practical tool to assist them in choosing the best treatment strategy for such patients. " 11/01/2006 - "GLH resistant T(1) plants were further evaluated for the incidence of tungro disease, caused by co-infection of GLH vectored Rice tungro bacilliform virus (RTBV) and Rice tungro spherical virus (RTSV), which appeared to be dramatically reduced. " 06/01/2006 - "In vivo priming protocols that preferentially induced one of the different CD8(+) T cell subsets demonstrated that predominance of T(EM) (CD40 stimulation) correlated best with effective protection against L.m., whereas generation of neither T(CM) (by immunization with heat-killed L.m.) nor T(EC) (by systemic co-administration of CpG during primary infection) conferred substantial long-term protective immunity. "
2.	Neoplasms (Cancer) 01/01/2015 - "One of the great success stories of modern medicine is undoubtedly the remarkable improvement in outcome for childhood cancer, achieved through the work of the co-operative groups enrolling patients in randomised controlled trials. " 01/01/2013 - "The discovery and subsequent ultrastructural characterization of the interstitial Cajal like cells (now called telocytes) in virtually every anatomic sites of the human body, by Laurentiu M Popescu and co-workers, have dramatically improved the understanding the function of these cells and pathogenesis of extragastrointestinal stromal tumors (EGIST). " 07/16/2010 - "Because Akt is active in most cancer cells and phosphorylated MADD confers resistance to TRAIL-induced apoptosis, co-targeting Akt-MADD axis is likely to increase efficacy of TRAIL-based therapies." 01/01/2010 - "stomach fundus, small bowel) showed distinct regional co-localization of Ngb, Cygb and CA IX. In most tumors, Ngb immunoreactivity was significantly greater than that of Cygb. " 05/01/2009 - "The combination of advanced age and co-existence of two neoplasms challenges the planning of the best treatment option. "
3.	Weight Loss (Weight Reduction) 06/01/2005 - "The small number of side effects and complications, the excellent weight loss and the recovery of most co-morbidity leads to a great improvement in quality of life." 07/01/2014 - "Revision of a failed RYGB or conversion of a VBG to a RYGB provides less weight loss and a higher complication rate than primary RYGB but provides an excellent opportunity for co-morbidity remission." 11/01/2007 - "All co-morbidities resolved completely with the weight loss. " 09/01/2015 - "We have observed good results in terms of weight loss and co-morbidity improvement/remission. " 07/01/2015 - "At 3 years, despite less favorable impact on weight than for younger patients, LRYGB provided significant weight loss and remission of co-morbidities for patients aged > 60 years. "
4.	Pain (Aches) 06/01/2003 - "This technique can provide more hemodynamic stability and better pain control than general alternative, MAC with local, is an extremely safe and effective technique for the EVAAR procedure, especially in patients with severe co-existing diseases. " 10/01/1999 - "Tolerance, defined as loss of opioid efficacy with time, is extremely variable and depends on pain mechanisms, intrinsic efficacy and administration modality of the opioid, as well as co-administration of other agents. " 04/01/2015 - "The intervention group also developed fewer keratotic lesions (mean difference -1.4, -2.5 to -0.2, p = .021), were less likely to report the use of co-interventions (relative risk [RR] 0.74, 0.56 to 0.98, p = .026) and were more likely to report that their foot pain had moderately or markedly improved during the study (RR = 7.93, 2.51 to 25.00, p < .001; number needed to treat = 3, 2 to 5). " 10/01/2010 - "There was a marked decrease in the co-activation of the bilateral gluteus medius muscles in the known pain developers when standing on the sloped surface compared with level standing. " 08/01/2015 - "Our interposition myoplasty technique with individualised pain/tone management has good outcomes in this cohort of patients with multiple co-morbidities."
5.	Obesity 05/01/2008 - "It has been proven in many studies that for severely obese patients there is no other more effective treatment of their obesity and co-morbidities than bariatric. " 01/01/2015 - "Despite a high psychological co-morbidity of obesity surgery patients the majority of studies also with follow-ups of more than 5 years demonstrates an improvement in mental functioning and quality of life. " 01/01/2015 - "Postoperatively, all obesity-related co-morbidities were significantly improved. " 05/01/2004 - "BMI fell significantly in both groups, with significant improvement of obesity-related co-morbidities. " 03/01/2014 - "LAGB as a primary treatment for obesity in carefully selected patients aged ≥ 70 can be well tolerated and effective with moderate resolution of co-morbid conditions and few complications."

Related Drugs and Biologics

1.	Carbon Monoxide
2.	Antigens
3.	DNA (Deoxyribonucleic Acid)
4.	Oxygen
5.	Vaccines
6.	Ribavirin (Virazole)
7.	Doxorubicin (Adriamycin)
8.	Small Interfering RNA (siRNA)
9.	Interferons
10.	Glucose (Dextrose)

Related Therapies and Procedures

1.	Lasers (Laser)
2.	Drug Therapy (Chemotherapy)
3.	Bariatric Surgery
4.	Transplants (Transplant)
5.	Transplantation (Transplant Recipients)